Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Status:
Terminated
Trial end date:
2017-04-25
Target enrollment:
Participant gender:
Summary
This is a Phase I/II trial of the combination pegylated IFN-alpha 2b with ixazomib in
metastatic renal cell carcinoma (mRCC). Researchers believe that by disabling the protein
complex NF-kB, which controls the transfer of genetic information; using the study drug
Ixazomib, they can promote necrotic cell death of RCC using interferon alpha - 2b. They
hypothesize that the combination of ixazomib with IFN will lead to increased necrotic cell
death in RCC tumors and consequent clinical benefit to patients.
Patients will receive ixazomib capsules and pegylated IFN alfa 2b injection in this research
study. Treatments will be given weekly and 4 weeks of treatment make up one cycle.